CTLA4 and rectal cancer: 96). In subcutaneous mouse models, expression of TIGIT was increased in response to administration of 3 × 8 Gy radiation (Ref. 97). When TIGIT and PDL1 were blocked in combination with RT pCR was 90% compared with 80% in mice treated with anti-PDL1 and radiation (Ref. 97). Recent clinical trials have investigated the combination of CTLA-4 inhibitors with PDL1 inhibitors and low dose fractionated or hypo-fractionated RT in stage 4 microsatellite stable rectal cancer patients (n = 18). Data were inconclusive and suggestive of high levels of toxicity (Ref. 98).